Michael A. Metzger - Jul 5, 2022 Form 4 Insider Report for CTI BIOPHARMA CORP (CTIC)

Role
Director
Signature
/s/ Bruce Seeley, attorney-in-fact for Michael A. Metzger
Stock symbol
CTIC
Transactions as of
Jul 5, 2022
Transactions value $
-$479,107
Form type
4
Date filed
7/7/2022, 05:02 PM
Previous filing
Mar 11, 2022
Next filing
Jul 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTIC common stock Options Exercise $77K +91.5K +454.75% $0.84* 112K Jul 5, 2022 Direct
transaction CTIC common stock Sale -$52K -8.7K -7.79% $5.98 103K Jul 5, 2022 Direct F1, F2
transaction CTIC common stock Sale -$314K -52K -50.49% $6.05 51K Jul 5, 2022 Direct F1, F3
transaction CTIC common stock Sale -$169K -27.5K -53.98% $6.14 23.5K Jul 5, 2022 Direct F1, F4
transaction CTIC common stock Sale -$20.7K -3.33K -14.2% $6.23 20.1K Jul 5, 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTIC Non-Qualified Stock Option (right to buy) Options Exercise $0 -91.5K -76.25% $0.00 28.5K Jul 5, 2022 Common Stock 91.5K $0.84 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person.
F2 Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.95 to $ 5.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F3 Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.00 to $ 6.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F4 Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.11 to $ 6.20. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F5 Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.21 to $ 6.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F6 The shares underlying the option were fully vested on May 16, 2020, the date that is twelve months after the date of grant.